ConductScience.org, home
Cell lines
API referenceFor AI assistants

Cell line · CVCL_1259

HCC1954

Cancer cell line, Homo sapiens. Breast ductal carcinoma. 75 papers.

4 sourcescell-lines-2026-11-14-0.1.0

Download JSON
Cite this record

ConductScience Library. HCC1954. Cell lines, record CVCL_1259. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1259

On this page

Cell line

As Cellosaurus gives it.

Name
HCC1954
Accession
CVCL_1259
RRID
RRID:CVCL_1259
Synonyms
HCC-1954, Hamon Cancer Center 1954
Species
Homo sapiens (Human)
Sex
Female
Age at sampling
61Y
Category
Cancer cell line
Diseases
Breast ductal carcinoma (NCIt C4017)
Derived from
Breast (in situ)
Entry created
2012-04-04
Entry updated
2025-08-14

Source Cellosaurus

Problems0

Cellosaurus records no problem for this cell line.

None in this release.

Papers75

PaperJournalYearHow we knowRetractedSource
Toward Personalized Theranostics: A Modular PET Platform for Antibody-Based Imaging and Therapy.Adv Sci (Weinh)2026Its Methods give the RRID and name the linePubMed
Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation.Mol Oncol2026Its Methods give the RRID and name the linePubMed
Design optimization of antibody-ligand motifs to enhance CAR-T redirection activity against solid tumors.Cell Rep Med2026Its Methods give the RRID and name the linePubMed
AXL-SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers.NPJ Precis Oncol2026Its Methods give the RRID and name the linePubMed
HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies.Cancer Discov2026Its Methods give the RRID and name the linePubMed
Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer.Clin Cancer Res2026Its Methods give the RRID and name the linePubMed
TPP-45142-an Anti-HER2 T-cell Engager-Designed for Selective HER2-Low Cancer Immunotherapy.Mol Cancer Ther2026Its Methods give the RRID and name the linePubMed
PM534, a Novel Colchicine Site Tubulin Inhibitor with Broad-Spectrum and Resistance-Overcoming Antitumor Activity.Mol Cancer Ther2026Its Methods give the RRID and name the linePubMed
In Vivo Auto-tuning of Antibody-Drug Conjugate Delivery to Maximize Efficacy Using High-Avidity, Low-Affinity Antibodies.Mol Cancer Ther2026Its Methods give the RRID and name the linePubMed
PTEN Loss Promotes PI3Kβ Phosphorylation and EPHA2/SRC/p-PI3KβY962 Complex Assembly to Drive Tumorigenesis.Cancer Discov2026Its Methods give the RRID and name the linePubMed

1 to 10 of 75

See all 75 papers

Relatives6

RelationCell lineAccessionProblemSource
Derived from itHCC1954-LRCVCL_LG20Cell lines
Derived from itHCC1954-LucCVCL_4W93Cell lines
Derived from itHCC1954-NRCVCL_LG21Cell lines
Derived from itHCC1954-TGLCVCL_VR24Cell lines
Derived from itHCC1954/TDRCVCL_B3MMCell lines
From the same personHCC1954 BLCVCL_1260Cell lines

Cell banks4

Cell bankCatalog numberStatusSource
ATCCCRL-2338ATCC
BCRJ0280BCRJ
CLS305268CLS
KCLB9S1954KCLB

Data dates

The date of each source this release read.

Cellosaurus
2026-10-22
Cellosaurus
PubMed Central's articles
2026-11-12
PubMed Central's articles
Our copy of PubMed
2026-11-06
Our copy of PubMed

Sources 4

  • CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
  • PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
  • NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
  • PubMedNLM's terms
Each source's terms
  • CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
  • PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
  • NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
  • PubMedNLM's terms

Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.

For software

Read this cell line from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/cell-lines/v1/CVCL_1259

GET https://conductscience.org/api/cell-lines/v1/CVCL_1259/papers?page=2

API referenceFor AI assistants